Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Model‐informed drug development (MIDD) approaches have rapidly advanced in drug development in recent years. Additionally, the Prescription Drug User Fee Act (PDUFA) VI has specific commitments to further enhance MIDD. Tumor growth dynamic (TGD) modeling, as one of the commonly utilized MIDD approaches in oncology, fulfills the purposes to accelerate the drug development, to support new drug and biologics license applications, and to guide the market access. Increasing knowledge of TGD modeling methodologies, encouraging applications in clinical setting for patients’ survival, and complementing assessment of regulatory review for submissions, together fueled promising potentials for imminent enhancement of TGD in oncology. This review is to comprehensively summarize the history of TGD, and present case examples of the recent advance of TGD modeling (mixture model and joint model), as well as the TGD impact on regulatory decisions, thus illustrating challenges and opportunities. Additionally, this review presents the future perspectives for TGD approach.

• Publication year

  2020

• Venue

  CPT: Pharmacometrics & Systems Pharmacology

• Publication date

  2020-06-26

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1002/psp4.12542PMID 32589767PMCID 7438808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer

  2020cited by this paper
• COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

  2020cited by this paper
• Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

  2020cited by this paper
• Management of Lung Cancer During the COVID-19 Pandemic.

  2020cited by this paper
• Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation

  2020cited by this paper
• Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

  2019cited by this paper
• A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors

  2019cited by this paper
• A Review of Cell-Based Computational Modeling in Cancer Biology

  2019cited by this paper
• Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow‐Up

  2019cited by this paper
• Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington’s disease

  2018cited by this paper
• Joint longitudinal and time-to-event models for multilevel hierarchical data

  2018cited by this paper
• A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review

  2018cited by this paper
• Cellular cooperation shapes tumor growth: a statistical mechanics mathematical model

  2018cited by this paper
• Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2017cited by this paper
• Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

  2017cited by this paper
• Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning

  2017cited by this paper
• Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

  2017cited by this paper
• A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

  2016cited by this paper
• How electromagnetic fields can influence adult stem cells: positive and negative impacts

  2016cited by this paper
• PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor

  2016cited by this paper
• Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

  2015cited by this paper
• The mathematics of cancer: integrating quantitative models

  2015cited by this paper
• Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

  2014cited by this paper
• Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

  2014cited by this paper
• The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making

  2013cited by this paper
• Accelerated approval of oncology products: the food and drug administration experience.

  2011cited by this paper
• A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

  2011cited by this paper
• Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

  2010cited by this paper
• Multiscale cancer modeling.

  2010cited by this paper
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

  2009influential reference
• Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

  2009cited by this paper
• Multiscale modelling and nonlinear simulation of vascular tumour growth

  2009cited by this paper
• Finding, evaluating, and managing drug‐related risks: approaches taken by the US Food and Drug Administration (FDA)

  2009cited by this paper
• A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype.

  2008cited by this paper
• Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro

  2008cited by this paper
• Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

  2008cited by this paper
• Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

  2004cited by this paper
• Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC).

  1989cited by this paper
• Predicting the course of Gompertzian growth

  1976cited by this paper
• Kinetics of tumor growth and regression in IgG multiple myeloma.

  1972cited by this paper
• Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

  1971cited by this paper
• EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

  1964cited by this paper
• Dynamics of Tumour Growth

  1964cited by this paper
• Time of occurrence of pulmonary metastasis from carcinoma of colon and rectum

  1962cited by this paper
• A biomathematical approach to clinical tumor growth

  1961cited by this paper
• Observations on growth rates of human tumors.

  1956cited by this paper
• A Comparison of the Growth Curves of Malignant and Normal (Embryonic and Postembryonic) Tissues of the Rat.

  1936cited by this paper
• On a Law of Growth of Jensen's Rat Sarcoma

  1932cited by this paper

• Optimal Dosage Justification for Datopotamab Deruxtecan in HR‐Positive/HER2‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches

  2026cites this paper
• Disease Modeling and External Model Evaluation Through Clinical Data Sharing Platform for HR+/HER2− Breast Cancer

  2025cites this paper
• Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

  2025cites this paper
• Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer

  2025cites this paper
• CanSeer: a translational methodology for developing personalized cancer models and therapeutics

  2025cites this paper
• Advancing drug development with “Fit-for-Purpose” modeling informed approaches

  2025cites this paper
• Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making

  2025cites this paper
• Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease Response

  2024cites this paper
• Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics

  2024cites this paper
• Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models

  2024cites this paper
• Model-based analysis for investigating the impact of tumor size, lymphocyte and neutrophil on the survival of breast cancer 4T1 tumor-bearing mice.

  2024cites this paper
• Integrated modeling of biomarkers, survival and safety in clinical oncology drug development.

  2024cites this paper
• Ten challenges and opportunities in computational immuno-oncology

  2024cites this paper
• Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

  2023cites this paper
• A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development

  2023cites this paper
• Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework

  2023cites this paper
• Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development

  2023cites this paper
• Translational Quantum Machine Intelligence for Modeling Tumor Dynamics in Oncology

  2022cites this paper
• An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft

  2022cites this paper
• CanSeer: A Method for Development and Clinical Translation of Personalized Cancer Therapeutics

  2022cites this paper
• Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma

  2022cites this paper
• Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis

  2022cites this paper
• Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients

  2022cites this paper
• Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study

  2022cites this paper
• Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

  2022cites this paper
• Mathematical Modeling the Time-Delay Interactions between Tumor Viruses and the Immune System with the Effects of Chemotherapy and Autoimmune Diseases

  2022cites this paper
• Machine Learning Methods for Predicting Tumor Volume in Rats after Termination of Complex Treatment with a Varying Dose of Cyclophosphamide

  2021cites this paper
• A Dynamic Model of Multiple Time-Delay Interactions between the Virus-Infected Cells and Body's Immune System with Autoimmune Diseases

  2021cites this paper
• Clone Wars: Quantitatively Understanding Cancer Drug Resistance.

  2020cites this paper